These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15471427)

  • 1. Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study.
    Suo Z; Karbovo E; Trope CG; Metodiev K; Nesland JM
    Ultrastruct Pathol; 2004; 28(3):141-7. PubMed ID: 15471427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features.
    Suo Z; Nesland JM
    Ultrastruct Pathol; 2000; 24(6):371-81. PubMed ID: 11206334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
    Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
    Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.
    Halperin R; Zehavi S; Dar P; Habler L; Hadas E; Bukovsky I; Schneider D
    Eur J Gynaecol Oncol; 2001; 22(4):292-6. PubMed ID: 11695812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
    Halperin R; Zehavi S; Hadas E; Habler L; Bukovsky I; Schneider D
    Int J Gynecol Pathol; 2001 Oct; 20(4):341-5. PubMed ID: 11603217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma.
    Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A
    Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
    Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
    Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
    Raju U; Fine G; Greenawald KA; Ohorodnik JM
    Hum Pathol; 1989 May; 20(5):426-36. PubMed ID: 2707793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
    Marinaş MC; Mogoş G; Ciurea R; Mogoş DG
    Rom J Morphol Embryol; 2012; 53(3):563-7. PubMed ID: 22990547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms.
    Harlozińska A; Bar JK; Sobańska E; Goluda M
    Tumour Biol; 1998; 19(5):364-73. PubMed ID: 9701727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
    Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the ErbB family of receptors in ovarian cancer.
    Scoccia B; Lee YM; Niederberger C; Ilekis JV
    J Soc Gynecol Investig; 1998; 5(3):161-5. PubMed ID: 9614647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content.
    Prat J; Oliva E; Lerma E; Vaquero M; Matías-Guiu X
    Cancer; 1994 Sep; 74(6):1778-83. PubMed ID: 7915964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.
    Henzen-Logmans SC; Fieret EJ; Berns EM; van der Burg ME; Klijn JG; Foekens JA
    Int J Cancer; 1994 May; 57(4):468-72. PubMed ID: 8181851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serous tumors of the ovary: ultrastructural observations.
    Franchina M; Del Borrello E; Caruso A; Altavilla G
    Eur J Gynaecol Oncol; 1992; 13(3):268-76. PubMed ID: 1618226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma.
    Malekzadeh M; Dehaghani AS; Ghaderi A; Doroudchi M
    Cancer Biomark; 2013 Jan; 13(6):417-25. PubMed ID: 24595078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.